安徽华人健康医药股份有限公司 内幕信息知情人登记管理制度 第一章 总则 董事会秘书具体负责公司内幕信息的日常管理工作，证券部是公司信息 披露管理、投资者关系管理、内幕信息登记备案的日常办事机构。 公司审计委员会对内幕信息知情人登记管理制度实施情况进行监督。 第二章 内幕信息及内幕信息知情人的范围 第六条 本制度所指内幕信息是指根据《证券法》相关规定，涉及公司的经营、 财务或者对公司股票、证券及其衍生品种交易价格有重大影响的尚未公 开的信息。包括但不限于： 1 第一条 为进一步规范安徽华人健康医药股份有限公司（以下简称"公司"）内幕 信息管理，加强公司内幕信息保密工作，维护信息披露的公平原则，保 护广大投资者的合法权益。根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司信息披露管理办法》《上市公司监管指引第 5号——上市公司内幕信息知情人登记管理制度》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号— —创业板上市公司规范运作》等有关法律法规、规范性文件及《安徽华 人健康医药股份有限公司公司章程》（以下简称"《公司章程》"）的有 关规定，结合公司实际情况，制定本制度 ...

安徽华人健康医药股份有限公司 董事会秘书工作细则 第一章 总则 董事会秘书为履行职责有权了解公司的财务和经营情况，参加涉及信 息披露的有关会议，查阅涉及信息披露的所有文件，并要求公司有关 部门和人员及时提供相关资料和信息。 2 第六条 公司董事会秘书的主要职责包括： (一) 负责处理公司信息披露事务，协调公司信息披露工作，组织制 订公司信息披露管理制度，督促公司和相关信息披露义务人遵 守信息披露相关规定； (二) 负责公司投资者关系管理和股东资料管理工作，协调公司与证 券监管机构、股东及实际控制人、证券服务机构、媒体等之间 的信息沟通； (三) 组织筹备董事会会议和股东会，参加股东会、董事会会议及高 级管理人员相关会议，负责董事会会议记录工作并签字确认； (四) 负责与公司信息披露有关的保密工作，在未公开重大信息泄露 时，及时向监管机构报告； (五) 关注媒体报道并主动求证真实情况，督促董事会及时回复深圳 证券交易所问询； (六) 组织董事、高级管理人员进行证券法律法规和深圳证券交易所 相关规则的培训，协助前述人员了解各自在信息披露中的权利 和义务； (七) 督促董事、高级管理人员遵守证券法律法规、《上市规则 ...

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].

Group 1 - Aike Cyber (688719.SH) shareholders Dachen Chuangtong and Dachen Chuanghong reduced their holdings by 2,298,151 shares, accounting for 1.99% of the total share capital, and did not complete the planned reduction [1] - Benchuan Intelligent (300964.SZ) controlling shareholder Dong Xiaojun reduced his holdings by 355,787 shares, accounting for 0.4582% of the total share capital, bringing his shareholding down to 21.64% [1] - Changlian Co., Ltd. (603648.SH) completed its reduction plan by selling 3,624,050 shares, which is 1% of the total share capital [1] Group 2 - Chuan Yi Technology (002866.SZ) controlling shareholder Zou Weimin and his concerted party reduced their holdings, with Zou's shareholding dropping to 48.53% [2] - Daoshi Technology (300409.SZ) controlling shareholder Rong Jihua plans to reduce his holdings by up to 15,416,611 shares, accounting for 1.97% of the total share capital [2] - Electric Alloy (300697.SZ) completed its reduction plan by selling 2,741,390 shares, which is 0.63% of the total share capital [2] Group 3 - Fujirei (688272.SH) shareholders Suzhou Kongkong, Suzhou Zhaorong, and Shanghai Zhaoren reduced their holdings by 1,215,618 shares, 1,463,490 shares, and 44,944 shares, accounting for 1.60%, 1.93%, and 0.06% of the total share capital respectively [3] - Gaoweida (300465.SZ) controlling shareholder Yingtan Yinggao Investment Consulting Co., Ltd. reduced its holdings by 4,261,700 shares, accounting for 0.96% of the total share capital, bringing its shareholding down to 22.00% [3] - Haizheng Materials (688203.SH) shareholder Sinopec Capital plans to reduce its holdings by up to 3,525,600 shares, accounting for 1.74% of the total share capital [3] Group 4 - Hangyu Micro (300053.SZ) shareholder Yan Jun reduced his holdings by 3,930,000 shares, accounting for 0.56% of the total share capital [4] - He Shi Eye Hospital (301103.SZ) shareholder Advanced Manufacturing Industry Investment Fund plans to reduce its holdings by up to 3,106,074 shares, accounting for 2% of the total share capital [4] - He Yuan Gas (002971.SZ) shareholder Baishide Chuangye completed its reduction plan by selling 854,064 shares, which is 0.415% of the total share capital [4] Group 5 - Huaren Health (301408.SZ) shareholder Saifu Investment reduced its holdings by 2,107,696 shares, accounting for 0.53% of the total share capital [5] - Jiangsu Boyun (301003.SZ) shareholder Gong Wei reduced his holdings by 1,558,900 shares, accounting for 1.57% of the total share capital [5] - Jeya Co., Ltd. (301108.SZ) shareholders Mingyuan Fund and its concerted party did not reduce their holdings, and the reduction plan period expired [5] Group 6 - Longxin General (603766.SH) directors plan to reduce their holdings by up to 350,000 shares and 100,000 shares, accounting for 0.0170% and 0.0049% of the total share capital respectively [6] - Ruchuang Micro-Nano (688002.SH) shareholder Li Weicheng plans to reduce his holdings by up to 8,000,000 shares, accounting for 1.75% of the total share capital [6] - Shilan Micro (600460.SH) shareholder Luo Huabing plans to reduce his holdings by up to 500,000 shares, accounting for 0.03005% of the total share capital [6] Group 7 - Tongfu Microelectronics (002156.SZ) shareholder National Integrated Circuit Industry Investment Fund reduced its holdings by 15,175,969 shares, accounting for 1% of the total share capital [7] - Wangzi New Materials (002735.SZ) controlling shareholder Wang Jinjun reduced his holdings by 9,717,874 shares, accounting for 2.54% of the total share capital [7] - Xingye Co., Ltd. (603928.SH) shareholder Shen Genzhen reduced his holdings by 2,620,000 shares, accounting for 1.00% of the total share capital [7] Group 8 - Yikang Co., Ltd. (301085.SZ) controlling shareholder concerted party reduced its holdings by 633,700 shares, accounting for 0.73% of the total share capital [8] Group 9 - Yiming Pharmaceutical (002826.SZ) major shareholder Zhou Zhan reduced his holdings by 3,586,777 shares, accounting for 1.88% of the total share capital [9] - Yiming Pharmaceutical (002826.SZ) director Xi Ke reduced his holdings by 283,862 shares, accounting for 0.15% of the total share capital [9] - Youyan Powder Materials (688456.SH) concerted party reduced its holdings by 1,030,000 shares, accounting for 0.99% of the total share capital [9] Group 10 - Zhongma Transmission (603767.SH) directors plan to reduce their holdings through block trading and centralized bidding [10] - Zhongqi Co., Ltd. (301215.SZ) shareholder Jiangsu Yueda Group did not reduce its holdings, and the reduction plan period expired [10]

Core Insights - The latest financing balance of the ChiNext market is 358.47 billion yuan, with a week-on-week increase of 3.90 billion yuan, indicating a positive trend in market financing activity [1] - A total of 40 stocks saw their financing balances increase by over 10%, while 16 stocks experienced a decline of more than 10% [1] Financing Balance Overview - As of June 30, the total margin balance for ChiNext stocks reached 359.50 billion yuan, marking an increase of 3.94 billion yuan from the previous trading day, continuing a six-day upward trend [1] - The financing balance specifically increased to 358.47 billion yuan, with a week-on-week rise of 3.90 billion yuan, also reflecting six consecutive days of growth [1] - The margin trading balance for short selling reached 1.03 billion yuan, with a week-on-week increase of 35.32 million yuan [1] Stocks with Significant Financing Balance Increases - Among the 527 stocks with increased financing balances, the stock with the highest increase is Huaren Health, which saw a financing balance of 95.80% growth, reaching 95.42 million yuan, and its stock price rose by 4.61% [1][3] - Other notable stocks with significant increases include Zhongguang Fanglei (72.52% increase) and Songsheng Co., Ltd. (62.77% increase) [1][3] Market Performance of Stocks with Increased Financing - Stocks with financing balance increases of over 10% averaged a rise of 5.10% on the same day, with 33 stocks experiencing gains, including three stocks that hit the daily limit [2] - The top gainers included Songsheng Co., Ltd. (13.73%), Guanshang Technology (13.22%), and Xinyu Guoke (11.85%) [2] Stocks with Decreased Financing Balances - A total of 406 stocks saw a decrease in financing balances, with 16 stocks experiencing declines of over 10% [4] - Wan Sheng Intelligent had the largest decrease, with a financing balance of 85.13 million yuan, down by 22.68% [4] - Other significant declines were observed in Ruina Intelligent (21.75% decrease) and Linuo Pharmaceutical Packaging (19.14% decrease) [4] Summary of Stocks with Decreased Financing Balances - The stocks with the largest decreases in financing balances include: - Wan Sheng Intelligent: 85.13 million yuan, -22.68% [4][5] - Ruina Intelligent: 46.40 million yuan, -21.75% [4][5] - Linuo Pharmaceutical Packaging: 158.80 million yuan, -19.14% [4][5]

证券代码：301408 证券简称：华人健康 公告编号：2025-046 安徽华人健康医药股份有限公司 关于合计持股 5%以上股东减持股份触及 1%的提示性 公告 公司股东苏州赛富璞鑫医疗健康产业投资中心 （有限合伙）、黄山赛富旅 游文化产业发展基金（有限合伙）、天津赛富盛元投资管理中心（有限合伙） －嘉兴腾元投资合伙企业 （有限合伙）、北京道同长菁投资管理中心 （有限合 伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 本次减持符合 中华人民共和国证券法》 上市公司股东减持股份管理暂行 办法》 上市公司董事和高级管理人员所持本公司股份及其变动管理规则》 深圳 证券交易所上市公司自律监管指引第 18 号——股东及董事、高级管理人员减持 股份》 证券期货法律适用意见第 19 号——＜上市公司收购管理办法＞第十三 条、第十四条的适用意见》等相关法律、法规、规章、业务规则的规定，不存在 相关法律、法规、规章、业务规则规定的不得减持股份的情形，亦未违反本企业 在 首次公开发行股票并在创业板上市招股说明书》及 首次 ...

Market Overview - On June 27, the Shanghai Composite Index fell by 0.7%, while the Shenzhen Component Index rose by 0.34% and the ChiNext Index increased by 0.47% [1] - A total of 52 stocks appeared on the daily trading list, with the highest net inflow of funds into Dawi Technology (600589.SH) amounting to 264 million yuan [1][4] Stock Performance - Dawi Technology saw a closing price increase of 6.61% with a turnover rate of 28.45%, and it accounted for 7.84% of the total trading volume [1][2] - The stock with the highest net outflow was Zhongfu Industrial (600595.SH), which experienced a net sell-off of 154 million yuan, representing 15.54% of its total trading volume, despite a closing price increase of 10.05% [4][6] Institutional Activity - Among the 27 stocks on the trading list, institutions were net buyers of 17 stocks and net sellers of 10 stocks, with a total net selling amount of 1.274 billion yuan [6][12] - The stock with the highest institutional net buying was Heertai (002402.SZ), which closed up by 10% and had a turnover rate of 13.07% [7] Northbound Capital - On June 27, northbound capital participated in 14 stocks, with a total net inflow of 915 million yuan [10] - The stock with the highest net inflow from northbound capital was Xiaoshangpin City (600415.SH), with a net purchase of 806 million yuan, accounting for 16.12% of its total trading volume [10][12] Summary of Key Stocks - The stocks that saw both institutional and northbound capital net buying included Hengbao Co., Maiwei Bio, Heertai, and Jinlongyu [12][14] - Conversely, stocks like Zhuyegroup and Zhongfu Industrial were net sold by both institutions and northbound capital [12][14]

Group 1 - Chinese Health saw a significant increase of 19.97%, reaching the daily price limit of 15% on June 27, driven by notable buying from well-known speculators [1] - The top five buying firms collectively purchased 125 million yuan, while the top five selling firms sold 123 million yuan, resulting in a net inflow of 1.67 million yuan [1] - Major buying firms included Guotai Junan Securities from Shanghai, with purchases of 29.93 million yuan, followed by Kaiyuan Securities from Xi'an with 24.77 million yuan, and Guotai Junan Securities from Nanjing with 22.94 million yuan [1] Group 2 - The largest selling firm was CITIC Securities from Beijing, which sold 58.25 million yuan, followed by the Shenzhen Stock Connect with 34.58 million yuan, and Huatai Securities from Hubei with 12.54 million yuan [2] - The net selling amounts for the top selling firms were significantly negative, with CITIC Securities showing a net outflow of 58.19 million yuan [2] - Other notable selling firms included Shenwan Hongyuan Securities from Xiamen and an institutional account, both showing negative net amounts [2]

证券代码：301408 证券简称：华人健康 公告编号：2025-045 安徽华人健康医药股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 安徽华人健康医药股份有限公司（以下简称"公司"或"本公司"）2024 年 年度权益分派方案已获2025年5月16日召开的2024年年度股东大会审议通过， 现将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1、公司 2024 年年度股东大会审议通过的利润分配方案为：以截至 2024 年 12 月 31 日公司总股本 400,010,000 股为基数，向全体股东每 10 股派发现金红 利 1 元（含税），共计派发现金红利 40,001,000.00 元（含税）。本次利润分配 不送红股，不以资本公积金转增股本，剩余未分配利润结转以后年度分配。 公司利润分配方案公布后至实施权益分派前，因股权激励行权、可转债转股、 股份回购等致使公司总股本发生变动的，公司将按照每股分配比例不变的原则， 对分配总额进行调整。 2、自上述利润分配方案披露至实施期间，公司股本总额未发生变化。 3 ...

证券代码：301408 证券简称：华人健康 公告编号：2025-044 安徽华人健康医药股份有限公司 关于收购福建、浙江三家医药连锁公司股权的进 展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易概述 安徽华人健康医药股份有限公司（以下简称"公司"）于 2025 年 5 月 19 日 召开第五届董事会第九次会议，以 9 票同意、0 票反对、0 票弃权的表决结果审 议通过了《关于收购福建、浙江三家医药连锁公司股权的议案》，同意公司以人 民币 13,342.90 万元的价格购买宁波闽哲汇投资合伙企业（有限合伙）（以下简 称"闽哲汇"）持有的福建省扬祖惠民医药连锁有限公司（以下简称"扬祖惠民"） 46.01%股权、以人民币 12,514.72 万元的价格购买闽哲汇持有的福建海华医药连 锁有限公司（以下简称"海华医药"）46.01%股权以及以人民币 6,825.975 万元 的价格购买闽哲汇持有的桐庐怡生堂大药房连锁有限公司（以下简称"桐庐怡生 堂"）70.01%股权。 公司于 2025 年 5 月 19 日与闽哲汇就前述三个目标公司的股权收购事宜分 别 ...